Ecotoxicological Effects of Lead and Copper on Seed Germination of Wheat

通过种子萌发试验,研究了不同浓度的Pb2+和Cu2+对小麦种子萌发、幼苗生长以及对小麦α-淀粉酶活性的生态毒理效应。结果表明:Pb2+在低浓度下(5Mg·l-1)对小麦种子萌发过程中的各项指标皆为抑制作用;Pb2+、Cu2+胁迫对小麦α-淀粉酶活性存在低浓度激活和高浓度抑制的效应,且浓度越高,抑制作用越强;Cu2+对小麦种子萌发各项指标的抑制率大于Pb2+,Pb2+、Cu2+对小麦根生长的毒害作用大于对地上部的影响。By seed germination experiments, We studied ecotoxicological effects of Pb2+, Cu2+ on the seed germination, seedling growth and α-amylase activity of wheat.The results showed that the seed germination and seedling growth of wheat could be promoted at low concentrations of Pb2+ (under 0.5 mg·L-1), while they would be inhibited when the concentration of Pb2+ was high; Cu2+ in high concentrations (above 5 mg·L-1) could reduce the germination rate, the seedling growth and vigor markedly; the activity of α-amylase could be enhanced at low concentrations of Pb2+ or Cu2+ but be inhibited at high concentrations, and the injury became severer with the increase of concentration; the inhibition of Cu2+ on seedling growth indices of wheat were larger than that of Pb2+, the stress effects of Pb2+ or Cu2+ was stronger on seed germination than seedling growth.国家高技术研究发展计划(863计划)项目(2007AA10Z441);上海市科委项目(07DZ12055);上海市科委项目(07JC14025

Effects of Cadmium Stress on Seed Germination and Seedling Growth of Dwarf Beans

为比较系统地探讨Cd2+的生物毒性,作者以水培法研究了不同浓度的Cd2+溶液对四季豆种子萌发和幼苗生长发育过程中植物外部生长指标及内部生理生化变化的影响。结果表明:当Cd2+浓度较低时,Cd2+对种子萌发及幼苗生长发育毒害作用较小,一定浓度范围内(0.05~0.5Mg/l)还有促生作用,高浓度Cd2+(5~100Mg/l)能严重抑制四季豆幼苗根及下胚轴的生长;Cd2+胁迫对四季豆幼苗体内过氧化物酶(POd),超氧化物歧化酶(SOd),过氧化氢酶(CAT)活性存在低浓度激活和高浓度抑制的效应,且同一浓度的Cd2+对四季豆幼苗POd、CAT活性的抑制作用表现为根系大于下胚轴,Cd2+浓度>0.5Mg/l时,根系SOd活性大于下胚轴中的活性;Cd2+胁迫下,四季豆下胚轴和根的丙二醛(MdA)含量增加,且根部含量大于下胚轴的量。Cd2+对矮生四季豆种苗生长发育的影响因Cd2+浓度及幼苗部位的不同而异。In order to explore the biological toxicity of Cd2+more systematically, the effects of Cd2+ on the external and internal physiological and biochemical changes in the process of dwarf beans seed germination and seedling growth were studied with hydroponic culture experiments.The results showed that when the concentration of Cd2+ at low level, the effects of Cd2+ on the seed germination and seedling growth were not significant.Seeds germination were activated at a certain extent when Cd2+ concentration ranged from 0.05mg/L to 0.5 mg/L concentrations.The roots and Hypocotyls of seedling exhibited a significant decrease in growth at higher level of Cd2+ concentrations (5～100mg/L).The activities of peroxidase (POD), superoxide dismutase (SOD), catalase (CAT)could be enhanced at low Cd2+concentrations but inhibited at higher concentration.The activities of POD, CAT were more inhibited in roots than in Hypocotyls at the same Cd2+ concentrations, while that of SOD was higher in roots than in Hypocotyls when the concentration of Cd2+ was more than 0.5mg/L.The malondialdehyde (MDA) contents were continuously increased with Cadmium exposure in both roots and Hypocotyls.The effects of Cd2+on the dwarf beans’growth were varied with the concentration of Cd2+ and the parts of plants.“2007AA10Z441”项目的资助;“07JC14025”项目的资助;“07DZ12055”项目的资

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials